Autologous Stem Cell Transplantation for Multiple Sclerosis

Area of Science:

• Neuroimmunology
• Stem Cell Transplantation
• Autoimmune Disorders

Background:

• Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative disease of the central nervous system.
• Current disease-modifying therapies (DMTs) are the standard of care but are often insufficient for patients with persistent disease activity.
• Autologous hematopoietic stem cell transplantation (AHSCT) is an alternative for treatment-resistant cases.

Purpose of the Study:

• To review the current evidence on the efficacy and outcomes of AHSCT in treating multiple sclerosis.
• To focus on optimal timing, transplant outcomes, and conditioning regimens for AHSCT.
• To compare AHSCT outcomes with existing DMTs and explore future therapeutic comparisons.

Main Methods:

• Systematic review of existing studies and clinical data on AHSCT for MS.
• Analysis of patient outcomes, including remission rates, disease activity, and neurological status.
• Evaluation of conditioning regimens and treatment-related mortality associated with AHSCT.

Main Results:

• AHSCT demonstrates high rates of sustained remission and no evidence of disease activity (NEDA) in DMT-resistant relapsing-remitting MS (RRMS).
• AHSCT can prevent further debilitation and improve neurological outcomes in RRMS patients.
• AHSCT shows potential for slowing disease progression in progressive MS, with very low treatment-related mortality.
• AHSCT generally achieves higher NEDA rates and lower relapse rates compared to DMTs.

Conclusions:

• AHSCT is a highly effective therapeutic option for DMT-resistant RRMS, offering sustained remission and improved outcomes.
• Further research is required to optimize patient selection and conditioning regimens for AHSCT in MS.
• Comparative studies with emerging therapies like CAR T-cell therapy are needed to define the future role of AHSCT.